Article
Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
JAMA oncology - 1 Sept 2020
Geuzinge H Amarens, Obdeijn Inge-Marie, Rutgers Emiel J T, Saadatmand Sepideh, Mann Ritse M, Oosterwijk Jan C, Tollenaar Rob A E M, de Roy van Zuidewijn Diderick B W, Lobbes Marc B I, van 't Riet Martijne, Hooning Maartje J, Ausems Margreet G E M, Loo Claudette E, Wesseling Jelle, Luiten Ernest J T, Zonderland Harmien M, Verhoef Cees, Heijnsdijk Eveline A M, Tilanus-Linthorst Madeleine M A, de Koning Harry J
Abstract excerpt
Importance: For women with a 20% or more familial risk of breast cancer without a known BRCA1/2 (BRCA1, OMIM 113705; and BRCA2, OMIM 114480) or TP53 (OMIM 151623) variant, screening guidelines vary substantially, and cost-effectiveness analyses are scarce. Objective: To assess the cost-effectiveness of magnetic resonance imaging (MRI) screening strategies for women with a 20% or more familial risk for breast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.